HC Wainwright maintains Halozyme price target at $115/share
HC Wainwright & Co. maintained its price target for Halozyme Therapeutics at $115.00 per share, according to Benzinga ratings action coverage.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.